Hello, Welcome to Shine Consultant !
Summit & Event Shine Speaker Bureau Shine Advisor Shine Event Service
  • Summit & Event :
    With field research of markets and industries which is analyzed from a global strategic perspective by our professional teams, as well as hot topics which interest leadership and management, Shine Consultant provides you with one-stop platform of dialogue, practice -sharing and social network!
  • Shine Speaker Bureau:
    Committed to provide keynote speakers, executive learning masterclasses and boardroom advisory for global enterprises and institutions, each service provides a deeper and more interactive experience, especially for small, selected audiences and key individuals. We have the resources of the most influential business leaders and experts, who are the most outstanding representatives in their fields. Our team consists of experienced speech and event managers, and we focus on building long-term and in-depth partnerships.
  • Shine Advisor:
    As world-class insight network, we connects clients-decision makers with vetted subject matter experts-advisors. Our clients leverage the insights and perspectives shared by our advisors to stay informed and make better business decisions.We have over 600,000 Shine Advisors in 20 industries, which continues to grow every day.
  • Shine Event Service:
    Committed to be the world's most professional provider of industrial Summit & Event. We provide one-stop professional services, including investigating and planning, on-demand inviting, marketing and promoting, operating, project management, live& digital conference, each service is performed by an experienced professional team matched with long-term industrial resources. We focus on establishing long-term and in-depth partnerships.
Guest Information
发布时间: 2020 - 11 - 26
点击次数: 0
Positions: VP, Business Development and Alliances
Company: AstraZeneca
个人简介:
Mr. Chen Bing is currently VP of AstraZeneca China, Head of Alliances and Business Development. As a member of China Senior Management Team, he reports directly to Michael Lai, General Manager of AstraZeneca China.Bing joined AstraZeneca China in May 2013 and subsequently held various roles including Marketing Director, Regional Sales Director (Zhejiang and Jiangxi provinces) of GRA BU, and Executive Marketing Director of RIA BU where he led the formulation of the China Respiratory Market Acceleration and Shaping Plan, and contributed substantially in the subsequent execution phase across sales and marketing roles, turning respiratory TA into the AstraZeneca China growth engine. In July 2017, he was appointed VP of AstraZeneca China, Head of Alliances and Business Development. In the current role, Bing has led several China-market specific first-timer deals enriching local portfolios and strengthening AZ leadership in respiratory and CV, including a traditional Chinese medicine. Besides leading business development, Bing has also been leading a few China strategic initiatives, including AZ-CICC $1bn investment fund, Oxford Vaccine China supply, and iHospital.Bing possesses a wealth of multinational and cross-sector experience. Prior to joining AstraZeneca, he served at McKinsey & Company for almost seven years, as Associate Principal, Greater China, specializing in strategic consulting for healthcare and other related industries, the scope of his work spanning the entire healthcare value chain. Prior to joining McKinsey, he lived in North America for over 10 years where his focus was on IT- and Internet-related start-ups.Bing holds a Bachelor’s degree in Electrical and Computer Engineering from the University of British Columbia, and an MBA from MIT Sloan School of Management.
发布时间: 2020 - 11 - 26
点击次数: 0
Positions: Founder and CEO
Company: Unicar Therapy
个人简介:
waiting
发布时间: 2020 - 11 - 26
点击次数: 0
Positions: Co-founder and CSO
Company: Elpiscience
个人简介:
Dr. Hongtao Lu is currently co-founder and Chief Scientific Officer (CSO) of Elpiscience Biopharma, a biotech company focusing on immuno-oncology. Trained as an immunologist and a 20-year industry veteran, he has worked on several therapeutic areas (autoimmune diseases, oncology and neuroscience) using both small-molecule and biological approaches. Before Elpiscience, he had spent four years with Zai Lab, a NASDAQ-listed company, as co-founder and CSO and helped to build a robust pipeline focusing on oncology and autoimmune diseases. Prior to Zai Lab, he was with GlaxoSmithKline as the founding head and senior director of Neuroimmunology Discovery Performance Unit (NI-DPU), where he led about 70 biologists and chemists focusing on drug discovery in multiple sclerosis and other neurodegenerative diseases including Parkinson's disease and had successfully built the team and the pipeline from scratch in 5 years with four clinical assets and four pre-clinical programs.Dr. Lu spent his early career with Berlex Biosciences and Bayer Schering Pharma, where he conducted target identification and validation in autoimmune inflammatory diseases and oncology. Dr. Lu holds a Ph.D. in Regulatory Biology and conducted his graduate research at the Cleveland Clinic Foundation, focusing on MHC class II gene regulation followed by post-doctoral fellowship at Yale University School of Medicine under the guidance of Dr. Richard Flavell, working on T cell differentiation and signal transduction pathway. He got his Bachelor degree at the Biology Department of Xiamen University in 1987.
发布时间: 2020 - 11 - 26
点击次数: 0
Positions: Founder, Chairman of our Board, CEO
Company: SinoMab Bioscience
个人简介:
Dr. Shui On LEUNG has nearly 30 years of experience in the field of molecular immunology and therapeutic monoclonal antibodies. Dr. Leung is the first scientist who successfully developed humanised anti-CD22 antibody in the U.S. and the first scientist who introduced the concept of “Functional Humanisation” in the world. Dr. Leung has been a member of the Biotech Advisory Panel of The Stock Exchange of Hong Kong Limited (“HKEx”) since its establishment and an adjunct professor of The Hong Kong University of Science and Technology. He was an executive director of a U.S. leading antibody-drug conjugate company, the managing director of The Hong Kong Institute of Biotechnology Limited, an adjunct professor of Fudan University, China, the Army Medical University (formerly known as the Third Military Medical University), China and the Air Force Medical University (formerly known as the Fourth Military Medical University) and The Chinese University of Hong Kong.  SinoMab BioScience Limited, founded by Dr. Leung, was listed on the main board of the HKEx in November 2019.